Raise closed, search for fresh raises on Seedstage

Ann Arbor, MI

Advancing a novel drug delivery system to enhance chemotherapy effectiveness while reducing harmful side effects.

• Targeted drug delivery: PALM is designed to selectively deliver chemotherapy drugs directly to cancer cells while avoiding healthy tissues.
• Improved safety profile: Preclinical studies show reduced side effects such as nerve damage, nausea, and immune suppression compared to traditional chemotherapy.
• Broad market potential: The platform is initially focused on ovarian cancer but has applications across multiple cancer types.
• Strong leadership team: Led by experienced biotech entrepreneurs with a track record of success in pharmaceutical innovation and exits.
• Significant industry validation: The PALM platform has been tested against 60 known cancer cell lines and demonstrated promising results.
• Scalable innovation: The technology is designed to be used with multiple approved chemotherapy drugs, creating future opportunities for licensing and expansion.

Peptinovo Biopharma is raising funds to advance the development of its smart drug delivery platform, PALM, which is designed to improve the safety and efficacy of chemotherapy. Traditional chemotherapy treatments often cause severe side effects that limit dosing and impact patient survival. The PALM system targets cancer cells by mimicking HDL, or “good cholesterol,” to deliver chemotherapy drugs directly into tumor cells while sparing healthy tissues. This approach has the potential to reduce side effects like nerve damage, nausea, and immune suppression, allowing for higher drug doses and improved treatment outcomes.

The funds raised will support critical steps toward human clinical trials, including scaling production, completing preclinical safety studies, and regulatory filings. Peptinovo has demonstrated PALM’s effectiveness in animal studies, showing equal or improved tumor suppression compared to standard chemotherapy while minimizing harmful side effects. With a focus on ovarian cancer as the first target indication, Peptinovo’s approach has broad applicability across multiple cancer types. Investors in this offering will support a novel oncology platform with the potential to disrupt the $124 billion chemotherapy market through improved drug delivery and patient outcomes.

Company Info

Peptinovo Biopharma develops a smart drug delivery platform to enhance chemotherapy effectiveness while reducing side effects.

Peptinovo Biopharma is a biotechnology company focused on improving cancer treatment through its proprietary drug delivery platform, PALM. The company has developed a smart drug delivery system that mimics high-density lipoproteins to target cancer cells while protecting healthy tissues. By leveraging this mechanism, Peptinovo aims to enhance the effectiveness of proven chemotherapy drugs while reducing harmful side effects such as nerve damage, nausea, and immune suppression. Its lead candidate combines PALM with paclitaxel, a widely used chemotherapy drug for cancers such as breast, ovarian, lung, prostate, and pancreatic.

Peptinovo’s approach addresses a critical need in oncology by providing a delivery system that specifically targets cancer cells, potentially improving survival rates while maintaining a higher quality of life for patients. The company has demonstrated promising preclinical results, showing tumor suppression comparable to standard treatments while significantly reducing toxicity. With a pipeline of PALM-based drug combinations, Peptinovo aims to disrupt the $124 billion oncology market by offering safer and more effective treatment options.